预约演示

Cellares secures $255m for cell therapy development facility

2023-08-24

细胞疗法基因疗法

The new IDMO smart factory at Bridgewater in New Jersey is spread over 118,000ft². Credit: Cellares.

Integrated development and manufacturing organisation (IDMO) Cellares has raised $255m in aCellaresC financing round for a cell therapy development facility at Bridgewater in New Jersey, US.

New investor Koch Disruptive Technologies led the funding round and its managing director David Mauney will join Cellares’s board of directors.

Recommended ReportsCellares Bridgewater

ReportsHead and Neck Squamous Cell Carcinoma - Global Drug Forecast and Market Analysis to 2030 GlobalDataCellares

ReportsLOA and PTSR Model - NKTR-255 in Squamous Cell Carcinoma GlobalData

View allCompanies IntelligenceBristol-Myers Squibb CoDecheng Capital LLCKoch Disruptive TechnologiesCellares CorpWillett Advisors LLCView all

The finHead and Neck Squamous Cell Carcinomaristol Myers Squibb, Willett Advisors and DFJ Growth, along with current investors Eclipse, Decheng Capital and 8VC.

To be spread over 118,000ft², the new commercial-scale IDMO smart factory will feature robotics, tailored technology and interconnected software.

The facility will manufacturNKTR-255 celSquamous Cell Carcinomally.

IDMO smart factories use combined technologies to manufacture ten times more cell therapy batches annually versus standard CDMO plants, utilising the same labour and footprint.

Cellares’s technology adoption partnership Bristol Myers Squibbollaboration of cell therapy developers in automating and transferring technology manual processes onto the manufacturing platform within six months.

This platform merges all the technologies needed to carry out the operations in the unit.

Cellares CEO Fabian Gerlinghaus stated: “The creation of the first IDMO marks the beginning of a new era, in which cell therapies will finally be able to reach those in need.

“We’ve developed integrated technologies for the entire drug development and manufacturing lifecycle.

Cellaresre leveraging these technologies to offer global manufacturing services for the living drugs of the 21st century.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Cellaresl content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构